1. Home
  2. IMAB vs EDAP Comparison

IMAB vs EDAP Comparison

Compare IMAB & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • EDAP
  • Stock Information
  • Founded
  • IMAB 2014
  • EDAP 1979
  • Country
  • IMAB United States
  • EDAP France
  • Employees
  • IMAB N/A
  • EDAP N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • IMAB Health Care
  • EDAP Health Care
  • Exchange
  • IMAB Nasdaq
  • EDAP Nasdaq
  • Market Cap
  • IMAB 87.2M
  • EDAP 81.6M
  • IPO Year
  • IMAB 2020
  • EDAP 1997
  • Fundamental
  • Price
  • IMAB $0.99
  • EDAP $2.51
  • Analyst Decision
  • IMAB Strong Buy
  • EDAP Strong Buy
  • Analyst Count
  • IMAB 3
  • EDAP 1
  • Target Price
  • IMAB $8.00
  • EDAP $19.00
  • AVG Volume (30 Days)
  • IMAB 354.5K
  • EDAP 42.1K
  • Earning Date
  • IMAB 03-13-2025
  • EDAP 03-26-2025
  • Dividend Yield
  • IMAB N/A
  • EDAP N/A
  • EPS Growth
  • IMAB N/A
  • EDAP N/A
  • EPS
  • IMAB N/A
  • EDAP N/A
  • Revenue
  • IMAB $3,313,984.00
  • EDAP $70,722,730.00
  • Revenue This Year
  • IMAB N/A
  • EDAP $6.96
  • Revenue Next Year
  • IMAB N/A
  • EDAP $15.53
  • P/E Ratio
  • IMAB N/A
  • EDAP N/A
  • Revenue Growth
  • IMAB N/A
  • EDAP 12.17
  • 52 Week Low
  • IMAB $0.84
  • EDAP $2.00
  • 52 Week High
  • IMAB $2.00
  • EDAP $8.50
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • EDAP 61.53
  • Support Level
  • IMAB $1.03
  • EDAP $2.15
  • Resistance Level
  • IMAB $1.10
  • EDAP $2.57
  • Average True Range (ATR)
  • IMAB 0.06
  • EDAP 0.14
  • MACD
  • IMAB -0.01
  • EDAP 0.04
  • Stochastic Oscillator
  • IMAB 7.58
  • EDAP 92.74

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: